ABACAVIR SULFATE AND LAMIVUDINE

Post-LOE

abacavir and lamivudine

Cipla

ANDAORALTABLET

Approved

Mar 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ABACAVIR SULFATE AND LAMIVUDINE (abacavir and lamivudine) by Cipla is nucleoside reverse transcriptase inhibitors [moa]. Approved for hepatitis b virus nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2017.

Drug data last refreshed 18h ago

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (3)

NCT04301661N/ACompleted

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

Started Mar 2020

25 enrolled

HIV-1-infection

NCT01656122Phase 2/3Completed

Abacavir and Lamivudine PK in Children

Started Jul 2012

30 enrolled

HIV

NCT00094367Phase 3Completed

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

Started Jul 2004

900 enrolled

HIV Infection

Company

Worked on ABACAVIR SULFATE AND LAMIVUDINE at Cipla? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.